Date published: 2026-2-14

1-800-457-3801

SCBT Portrait Logo
Seach Input

LAPTM4A Activators

LAPTM4A Activators comprise a diverse set of chemical compounds that indirectly enhance the functional activity of LAPTM4A, particularly in the domains of lysosomal function and autophagy. Forskolin, through its ability to elevate cAMP levels, indirectly boosts LAPTM4A activity by affecting lysosomal functions and membrane trafficking, key aspects of LAPTM4A's role. Chloroquine, impacting lysosomal acidity, also enhances LAPTM4A activity by modifying lysosomal functions and influencing autophagy-related processes, where LAPTM4A is involved. Rapamycin, as an mTOR inhibitor, plays a significant role in enhancing LAPTM4A activity by modulating autophagy pathways, a critical process in which LAPTM4A participates. Bafilomycin A1, a vacuolar H+-ATPase inhibitor, contributes to LAPTM4A activation by affecting lysosomal acidification and autophagy, processes central to LAPTM4A's functionality.

In a similar vein, U0126 and SB203580, inhibitors of MEK1/2 and p38 MAPK respectively, indirectly enhance LAPTM4A activity. They achieve this by altering signaling pathways that influence lysosomal function and autophagic processes, both of which are integral to LAPTM4A's role. 3-MA (3-Methyladenine) and Wortmannin, both PI3K inhibitors, also contribute to the enhancement of LAPTM4A activity by modulating autophagy, a key process where LAPTM4A exerts its function. Spautin-1, known for inhibiting autophagy, indirectly augments LAPTM4A activity by impacting autophagic flux and lysosomal function, further emphasizing the complex regulation of LAPTM4A in these processes. Torin 1, another mTOR inhibitor, enhances LAPTM4A activity by modulating both autophagy and lysosomal biogenesis, underlining the multifaceted role of LAPTM4A in these cellular processes. LY294002, also a PI3K inhibitor, plays a similar role in activating LAPTM4A by altering signaling pathways that govern autophagy and lysosomal functions. Lastly, Curcumin enhances LAPTM4A activity by influencing signaling pathways involved in autophagy and lysosomal function, crucial to LAPTM4A's role.

SEE ALSO...

Items 1 to 10 of 11 total

Display:

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

Forskolin

66575-29-9sc-3562
sc-3562A
sc-3562B
sc-3562C
sc-3562D
5 mg
50 mg
1 g
2 g
5 g
$78.00
$153.00
$740.00
$1413.00
$2091.00
73
(3)

Forskolin, by raising cAMP levels, can indirectly enhance LAPTM4A activity by influencing lysosomal function and membrane trafficking, where LAPTM4A is functionally significant.

Chloroquine

54-05-7sc-507304
250 mg
$69.00
2
(0)

Chloroquine, known to affect lysosomal acidity, can indirectly enhance LAPTM4A activity by altering lysosomal function and potentially influencing LAPTM4A-mediated processes in autophagy.

Rapamycin

53123-88-9sc-3504
sc-3504A
sc-3504B
1 mg
5 mg
25 mg
$63.00
$158.00
$326.00
233
(4)

As an mTOR inhibitor, Rapamycin can enhance LAPTM4A activity by modulating autophagy pathways, a process where LAPTM4A is involved.

Bafilomycin A1

88899-55-2sc-201550
sc-201550A
sc-201550B
sc-201550C
100 µg
1 mg
5 mg
10 mg
$98.00
$255.00
$765.00
$1457.00
280
(6)

This vacuolar H+-ATPase inhibitor can enhance LAPTM4A activity by impacting lysosomal acidification and autophagy, where LAPTM4A plays a role.

SB 203580

152121-47-6sc-3533
sc-3533A
1 mg
5 mg
$90.00
$349.00
284
(5)

As a p38 MAPK inhibitor, SB203580 can indirectly affect LAPTM4A activity by altering cellular stress responses and autophagic processes, where LAPTM4A is involved.

Autophagy Inhibitor, 3-MA

5142-23-4sc-205596
sc-205596A
50 mg
500 mg
$65.00
$261.00
113
(3)

This PI3K inhibitor can indirectly enhance LAPTM4A activity by modulating autophagy, a process in which LAPTM4A is functionally important.

Spautin-1

1262888-28-7sc-507306
10 mg
$168.00
(0)

Spautin-1, known to inhibit autophagy, can indirectly enhance LAPTM4A activity by affecting autophagic flux and lysosomal function.

Torin 1

1222998-36-8sc-396760
10 mg
$245.00
7
(1)

Torin 1, as an mTOR inhibitor, can enhance LAPTM4A activity by modulating autophagy and lysosomal biogenesis, processes where LAPTM4A is active.

Wortmannin

19545-26-7sc-3505
sc-3505A
sc-3505B
1 mg
5 mg
20 mg
$67.00
$223.00
$425.00
97
(3)

Wortmannin, another PI3K inhibitor, can indirectly enhance LAPTM4A activity by influencing autophagy and lysosomal function.

LY 294002

154447-36-6sc-201426
sc-201426A
5 mg
25 mg
$123.00
$400.00
148
(1)

LY294002, a PI3K inhibitor, can indirectly enhance LAPTM4A activity by altering signaling pathways that govern autophagy and lysosomal functions.